Related Experiment Video

Updated: May 10, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy

James V Alvarez1, Tien-Chi Pan, Jason Ruth

  • 1Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Cancer Cell
|June 18, 2013
PubMed

Insights

Par-4 protein levels decrease, promoting breast cancer recurrence by helping tumor cells evade cell death. Restoring Par-4 may be a strategy to prevent cancer relapse.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Breast cancer mortality is primarily driven by tumor recurrence, yet the underlying mechanisms remain poorly understood.
  • Identifying factors that regulate tumor relapse is crucial for improving patient outcomes and developing effective therapeutic strategies.

Purpose of the Study:

  • To investigate the role of Par-4 in breast cancer recurrence and its potential as a therapeutic target.
  • To elucidate the mechanisms by which Par-4 influences tumor cell survival and evasion of therapy-induced cell death.

Main Methods:

  • Analysis of Par-4 expression levels in relation to tumor recurrence and response to neoadjuvant chemotherapy in breast cancer patients.
  • Investigation of the functional role of Par-4 in regulating multinucleation and apoptosis in tumor cells following treatment.

Main Results:

  • Par-4 is significantly downregulated during breast cancer recurrence, and this downregulation is both necessary and sufficient to promote relapse.
  • Tumor cells with low Par-4 expression evade therapy-induced apoptosis and multinucleation, contributing to residual disease.
  • Low Par-4 expression correlates with poor response to neoadjuvant chemotherapy and an increased risk of breast cancer recurrence.

Conclusions:

  • Par-4 downregulation is a key mechanism driving breast cancer recurrence.
  • Par-4-induced multinucleation represents a novel cell death pathway in oncogene-addicted cancer cells.
  • Par-4 acts as a critical negative regulator of breast cancer recurrence, suggesting its potential as a therapeutic target.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...